In July 2021, the pharma industry reported 75 deals worth $26.6 billion as compared to the last 12-month average (July 2020 to June 2021) of 105 deals worth $26.6 billion, according to a GlobalData report.

The report also said that the acquisition of Parexel International Corp by EQT Partners AB and Goldman Sachs Asset Management for $8.5 billion; acquisition of Biolegend by PerkinElmer for approximately $5.2 billion; and acquisition of Teneobio by Amgen for $2.5 billion contributed 60.9 per cent of the total deal value during July 2021.

Apart from it, the report said that the industry also reported 112 venture capital (VC) deals worth $3.8 billion in July 2021, compared to the last 12-month average (July 2020 to June 2021) of 170 deals worth $5 billion.

“Prime Medicine, a biotechnology company, raising $200 million in series B round of financing to advance towards clinical indications, expand capabilities of the platform, and further enhance the exceptional promise of Prime Editing; Deep Genomics Inc, an artificial intelligence (AI) therapeutics company, raising $180 million in series C round of financing for ‘Programmable’ RNA therapeutics; and Wugen Inc, a clinical-stage biotechnology company, raising $172 million in series B funding to advance clinical-stage memory NK cell platform, progress Best-In-Class AML programme, and initiate Multiple Solid Tumour Trials, were the major VC deals reported in July 2021,” added the statement.